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appraisal of hyperthermic intraperitoneal
chemotherapy (HIPEC) in the treatment of
advanced and recurrent ovarian cancer”
by Chiva LM and Gonzalez-Martin A.We have read the recent review on the use of hyperthermic intra-
peritoneal chemotherapy (HIPEC) to treat advanced epithelial ovarian
cancer written by Chiva & Gonzalez-Martin and we remained deeply
concerned due to numerous severe imprecisions and misleading
reasoning of the authors (Chiva and Gonzalez-Martin, 2015).
After a systematic revision of the literature the authors focused the
analysis on the role of cytoreductive surgery and HIPEC in two time
points of the natural history of advanced epithelial ovarian cancer
(EOC): front line therapy and platinum sensitive recurrent disease.
They came to the conclusion that the average weighted median overall
and disease free survivals were 37.3 and 14.4 months, respectively for
cases treated with the combined procedure at front line and recurrent
disease.
A close analysis of Table 3 of the review, that gathers the information
on 248 patients from 11 studies on the use of the combined therapy in
front-line setting, leads us to raise two major criticisms: 1) the paper
by Massari et al. that contributed with only two patients should be ex-
cluded due to the small sample size; (Massari et al., 2014); and 2) calcu-
lating the weighted average of themedian OSs in this population of 248
patients is highly disputable as it penalizes the results of two studies in
which the survival outcome was so favorable that the median was not
reached. In the series by Roviello et al. the study was closed after a
median follow-up of 27 months and 5 year OS was 55% (Roviello et
al., 2010). On the other hand Deraco et al. reported a 5 year OS of
60.7% after a median follow-up of 25 months (Deraco et al., 2011). In
both studies the median OSs, if the follow-ups were longer, it could be
expected to be of at least of 60 months. If these hypothetical ﬁgures
were considered in the calculation of the weighted average of median
OS the results would be 42.1 months and not 37.3 months.
Moreover, we do not agree that the results obtained with
cytoreductive surgery and HIPEC in the ﬁrst-line setting could be com-
pared with those reported by Bookman et al., the largest cohort of ad-
vanced EOC patients ever reported in the context of a phase III clinical
trial (Bookman et al., 2009). Firstly, both populations have been staged
using different systems (Peritoneal Cancer Index vs. FIGO stage). Sec-
ondly, 85% of patients in the Bookman trial had FIGO stage III disease.
This does not necessarily mean that all these patients had extensive
peritoneal carcinomatosis, as stages IIIa and IIIb are characterized bymi-
croscopic peritoneal disease and peritoneal implants of less than 2 cm.DOI of original article: http://dx.doi.org/10.1016/j.ygyno.2014.11.072
http://dx.doi.org/10.1016/j.gore.2015.11.002
2352-5789/© 2015 The Authors. Published by Elsevier Inc. This is an open access article underConsidering that the average of peritoneal cancer index in patients
treated in primary setting with CRS and HIPEC was 14 it is reasonable
to consider that the cohort of patients from ICON-5 trial, on the average,
had at least less extensive peritoneal disease.
In any case, themajor caveat in the Chiva's review is the fact that the
authors focus their discussion on the role of HIPEC and simply ignore the
importance of cytoreductive surgery in the ﬁnal prognostic gain of ad-
vanced EOC patients. It is well known that the dimension of the residual
disease left behind after a cytoreductive surgery is the most powerful
determinant of the outcome (Chang et al., 2013).
They depart from the assumption that the so-called debulking surgery
performed by gynecologic oncologists is the same thing as the
cytoreductive surgery done by peritoneal surgeons. Be this assumption
true it could be troublesome to justify why in the recentmulticentric ran-
domized study by Vergot et al., only 42% of patients in the study group
submitted to upfront surgery had residual disease of less than 1 cm
(Vergote et al., 2010). Worse still, the overall rate of complete
cytoreduction was 19.4%. This unacceptably low rate of optimal surgeries
is likely a result of a nonproper surgical training inmultivisceral resection
surgeries and peritonectomy procedures and above all, to a lack of stan-
dardization of the so-called debulking surgery among gynecologic oncol-
ogists (Naik and Barton, 2010). Fortunately, there are some exceptions to
this trend in the gynecologic oncology ﬁeld. Dr. Chi et al. at the Memorial
Sloan Kettering have actively changed the attitude toward the issue of
surgical approach to EOC. They have started adopting a more aggressive
policy to treat advanced EOC by means of a multidisciplinary collabora-
tion with surgeons, especially to approach extensive disease in the
upper abdomenand this resulted in positive impact both in terms of over-
all and disease free survivals (Chi et al., 2009).
Another disputable issue approached by Chiva & Gonzalez-Martin is
that of morbidity and mortality related to the combined procedure. It is
unfair to highlight the results of the randomized trial, in which I myself
was the co-investigator, the rates of 57% of severe morbidity and 28% of
mortality. First, because these outcomes were calculated on a population
of 7 only patients recruited to the experimental arm during the entire pe-
riod of activity of the trial. Second, because the eligibility criteria for this
trial was platinum resistant recurrent or persistent disease after the com-
pletion of ﬁrst line chemotherapy – that represents a completely different
population from the subsets elected by Chiva. Third, the major reason for
the closure the trial was not the high rates of severe side effects but the
slow patient accrual.
We are aware that the conduction of systematic reviews is very chal-
lenging, especially in the ﬁeld of peritoneal surface malignancies, where
the level of evidence is still low. Althoughwe strongly agree with the au-
thors regarding the experimental nature of the combined treatment – the
motif why it should only be offered to patients in the context of a clinical
trial–, we cannot accept inaccurate and superﬁcial analysis that could lead
tomisleading and counterproductive conclusions. In any case, a deﬁnitive
answer regarding the actual contribution of cytoreductive surgery and
HIPEC in prognosis of advanced EOC will only be provided by the eagerly
awaited results from the ongoing randomized trial on this issue.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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